Plus Therapeutics Signs AI Platform Deal with Ephemeral Technologies for CNS Oncology Programs

Plus Therapeutics' agreement with Ephemeral Technologies signals a structural shift in how clinical-stage radiotherapeutic programs manage the convergence of therapeutic, diagnostic, and bioinformatics data, a challenge that has historically slowed translational decision-making in CNS oncology. The partnership, announced 19 May 2026, covers the design and deployment of an AI execution platform built to unify longitudinal datasets across Plus' leptomeningeal metastases and recurrent glioblastoma programs.

Ephemeral, founded by former co-heads of Palantir Technologies' U.S. healthcare business, will assess and implement AI-enabled data infrastructure to support integration, organization, and analysis of complex CNS oncology datasets generated through Plus' therapeutic and diagnostic workflows. No financial terms were disclosed. The platform is described as AI-native, incorporating generative AI reasoning and agentic workflows against multi-modal, longitudinal data.

For development operations and data management leads, the near-term scope is concrete: Plus anticipates measurable improvements in laboratory and clinical operating efficiency beginning in 2026. The longer horizon includes operational decision support, translational and treatment response analytics, patient stratification, and real-world evidence initiatives, functions that carry direct implications for protocol design, site monitoring, and regulatory submission packages.

Plus operates CNSide Diagnostics, LLC as a wholly owned subsidiary, which develops laboratory-developed tests to identify CNS-metastasized tumor cells. The integration of diagnostic data from CNSide into a unified AI platform adds a layer of complexity that will test the robustness of the underlying data governance architecture, particularly where laboratory-developed test outputs feed into clinical decision workflows subject to regulatory scrutiny.

The degree to which the platform delivers on patient stratification and translational analytics will become measurable as Plus advances its lead programs toward later-stage clinical milestones.

Source: GlobeNewswire via Plus Therapeutics press release, 19 May 2026.